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ABSTRACT: Carotid-femoral pulse wave velocity (PWV) is a gold standard non-invasive marker of arterial stiffness, but its clinical utili-
ty has been limited due to the need for normative and reference group data for specific measurement devices. Our community-based 
sample (N = 502) ranged in age from 40 to 93 years after exclusion of individuals with a history of acute stroke, probable dementia, 
and diabetes. PWV was assessed with the SphygmoCor® system. Means, medians, SD and 95th percentile values were presented in 
ten-year age groups for normotensive and hypertensive participants.  From among multiple cardiovascular risk factors, a parsimoni-
ous regression equation for predicting PWV was developed.  Results were compared with the Reference Values for Arterial Stiffness 
Collaboration (RVASC) study featuring mathematically standardized reference values for an aggregate of clinic sites and measure-
ment devices. As in the RVASC study, a systematic rise in PWV with age was observed with a more pronounced rise for hypertensive 
individuals, but our specific point estimates of PWV differed from theirs. Our regression models accounted for 48 percent of the vari-
ance in PWV using variables routinely available to practicing physicians: age, hypertension status, height, weight, heart rate, mean 
arterial pressure, creatinine, and glucose. It is important to make available PWV norms and reference group data for specific meas-
urement devices. Development of reference group data for smaller samples is feasible and prediction equations for PWV can be de-
veloped from diagnostic information readily available to the practicing physician. 
KEYWORDS: pulse wave velocity,  norms,  reference values,  risk factors, atherosclerosis  
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C arotid-femoral pulse wave velocity (PWV) is a gold standard non-invasive marker of arterial stiffness and is itself a predictor of cardiovascular morbidity and mortality *1-11+.  The clinical utility of PWV has been 
restricted by limited normative and reference group data, a situa-
tion exacerbated by differences in PWV measurement methods 
across studies *1-14+. The continuing need for normative and refer-
ence values for specific devices has been emphasized in studies 
comparing PWV measuring devices and meta-analyses *12-14+.  
There are norms and reference group data for study participants in 
good health by age and by combined hypertensive-diabetic status 
*12-19+, but to our knowledge, none exists for hypertensive (HT) 
and normotensive (NT) classifications by decades or HT and NT 
groups, except for the Reference Values for Arterial Stiffness Col-
laboration (RVASC) study *20+.  In the RVASC study, PWV data were 
gathered from 13 centers across eight European countries. Sub-
jects were classified as follows: optimal, normal, high normal, 
grade I, and grade II/III hypertensive blood pressure (BP) catego-
ries by age decades, including two additional groups not by decade 
but above 70 and below 30 years of age.  Results for five PWV 
measuring systems were combined, necessitating the merging of 
findings from centers using different algorithms and different esti-
mates of path length. Consequently, mathematical adjustments 
designed to equate transit time and path length estimates across 
studies were required.  The RVASC (20) investigators caution read-
ers that “Even after full adjustment, differences between algorithm 
and path length were blunted, but not totally abolished.” Moreo-
ver, they point out that there was a strong data collection center 
effect that was not accounted for by their standardization proce-
dures.   
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Thus, our goals were: first, provide normative and reference 
group data based on a single algorithm (intersecting tangent) em-
ployed in a single widely used system (SphygmoCor®); second, to 
compare our findings with those of the RVASC study in so far as 
possible, e.g. we present data for persons 80 to 93 years of age 
rather than combining groups above 70 years of age; and third, to 
determine a parsimonious regression model for predicting PWV 
beyond age, hypertension, and necessary control variables such as 
height and weight, heart rate and mean arterial pressure (MAP). 
Previous studies have explored relations between cardiovascular 
risk factors other than hypertension and age that predict PWV *6-
8+.  Here, we are concerned with the best prediction possible from 
the fewest variables beyond essential controls.    
METHODS 
Participants 
The PWV data were obtained from a community-based sample 
of 626 participants (61% women; 14% African American) ranging in 
age from 24 to 93 years (mean age 64.3). They were participants in 
PWV studies conducted for the first time in the seventh wave 
(repeated serial data collection) of the Maine Syracuse Longitudi-
nal Study (MSLS), which was initiated in 1975. Recruitment proce-
dures have been described previously *21-23+. Subjects were re-
cruited from the Syracuse, New York community and the surround-
ing area by means of multi-media advertisement for participation 
in a study of cognition and BP, and admitted to the study unless 
they were diagnosed as psychotic or alcoholic, or were receiving 
treatment for these diseases.  Upon diagnosis of hypertension at 
any wave, individuals were referred to their physician for treat-
ment and 88.6 percent were treated at wave 7.  
Carotid-femoral PWV (m/s) was measured for the first time at 
the seventh (final) wave (2006-2009) of the MSLS and cardiovascu-
lar disease (CVD) risk factor covariates from that wave were em-
ployed. Thus the present data analysis is cross-sectional.  In an 
initial analysis of the 626 participants for whom PWV data were 
obtained, subjects were excluded in the following sequence: (1) 
dementia (n=2); (2) history of acute stroke (n=14); (3) diabetes (n= 
93); and (4) under 40 years of age (n=15).  Individuals under 40 
years of age were excluded due to the small number of subjects in 
that range.  The final dementia-free sample consisted of 502 indi-
viduals. Cardiovascular risk factor and demographic data were 
available for an additional 174 persons meeting these criteria but 
missing PWV data. Their PWV values were derived by multiple 
imputations *24+, thus increasing the sample size to 676 for a sec-
ondary set of analyses.    
The clinical diagnosis of dementia was determined from cogni-
tive data and family informant-report, medical records or chart 
review *21-23+ using the National Institute of Neurological and 
Communicative Diseases and Stroke/Alzheimer’s Disease and Re-
lated Disorders Association (NINCDS-ADRDA) criteria *25+. Preva-
lent stroke, defined as a focal neurological deficit of acute onset 
persisting more than 24 hours, was based on self-report and rec-
ord review, confirmed by hospitalization, treatment for stroke, or 
both. Diabetes mellitus was defined by treatment with insulin, oral 
anti-diabetic agents, or by a fasting glucose level ≥ 7 mmol/l. MAP 
was calculated as diastolic BP+1/3 (systolic BP – diastolic BP). The 
demographic and cardiovascular morbidity characteristics of the 
sample are presented in Table 1 .  
Procedure 
The University of Maine approved this investigation and in-
formed consent for data collection was obtained from all partici-
pants. Participants were admitted to the study center on the day 
of the study, followed by medical history interview and then PWV 
measurements.  
Blood Pressure (BP) and Pulse Wave Assessment  
Brachial artery pressures were measured using a Critikon Di-
namap ProCare 100 (oscillometric method) instrument. All precau-
tions, training and procedures in BP measurement recommended 
by the Committee Report: Blood Pressure Publication Guidelines 
were observed *26+.  
Following 10 minutes of supine rest, 15 consecutive automated 
brachial BP measurements were taken at 1 minute intervals, 5 
supine, 5 standing, and 5 sitting. The resulting 15 measurements 
were averaged and used for analyses outlined below.  After an 
additional 10 minutes rest, five supine brachial artery BP measure-
ments were obtained, averaged and used for calibration of the 
SphygmoCor® device *27+. This procedure permitted us to maintain 
the BP measurement protocol that has been used since the since 
the beginning of the MSLS study and to obtain additional supine 
measurements for device calibration purposes.  
PWV was assessed noninvasively using the SphygmoCor® sys-
tem.  Electrocardiogram-gated carotid and femoral waveforms 
were recorded using applanation tonometry. Carotid-femoral path 
length was measured as the difference between the surface dis-
tances joining (1) the suprasternal notch, the umbilicus and the 
femoral pulse and (2) the suprasternal notch and the carotid pulse. 
Carotid-femoral transit time was estimated in 8-10 sequential fem-
oral and carotid waveforms as the average time difference be-
tween the onset of the femoral and carotid waveforms. The foot of 
the pulse wave was identified using the intersecting tangent meth-
od. PWV was calculated as the carotid-femoral path length divided 
by the carotid-femoral transit time *27-28+. This is an established, 
non-invasive and reproducible method to determine arterial stiff-
ness *10, 27-28+ and no adjustments are required for transit time 
and path length *29, 30+.  
Predictors and Covariables  
Hypertension was defined as taking anti-hypertensive medica-
tions at wave 7 or exhibiting an average (over 15 measurements) 
brachial artery systolic and diastolic BP equal to or greater than 
140/90 mmHg. The methods used to assess CVD risk variables and 
other covariates at wave 7 have been presented in detail previous-
ly *21-23+.  
Two major diagnostic groups were employed: (1) a NT group (n= 
206); and (2) a HT group (n= 296) using major selection criteria 
employed in the RVASC study (20) but with the inclusion of treated 
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  Normotensive Hypertensive   
n= 206 N= 296 
Age (years) 61.0 (11.7) 67.4 (11.3) <0.001 
PWV (m/s) 8.9 (2.0) 11.0 (2.9) <0.001 
BMI (kg/m2) 27.1 (5.1) 30.4 (6.2) <0.001 
Waist (cm) 86.4 (15.2) 96.5 (13.9) <0.001 
SBP (mmHg)1 116.6 (12.3) 137.4 (20.0) <0.001 
DBP (mmHg)1 73.2 (7.8) 79.9 (10.4) <0.001 
PP (mmHg)1 43.3 (10.0) 57.5 (16.4) <0.001 
MAP (mmHg)1 87.7 (8.3) 99.1 (12.1) <0.001 
HR (beats/min) 57.7 (7.9) 60.3 (9.6) 0.002 
Glucose (mg/dl) 88.6 (9.2) 94.6 (11.0) <0.001 
Creatinine (mg/dl) 1.0 (0.2) 1.1 (0.2) 0.006 
Cholesterol (mg/dl) 200.3 (37.4) 185.0 (39.2) <0.001 
HDL (mg/dl) 58.8 (16.4) 51.7 (14.6) <0.001 
LDL (mg/dl) 122.4 (31.1) 109.7 (33.2) <0.001 
Triglycerides (mg/dl) 97.3 (67.8) 117.5 (58.4) <0.001 
Total/HDL 3.6 (1.0) 3.8 (0.9) 0.10 
Alcohol (oz/wk) 1.4 (2.4) 1.5 (2.6) 0.59 
Cigarettes/wk 7.6 (38.3) 8.5 (34.1) 0.79 
Height (cm) 166.2 (9.2) 167.9 (10.5) 0.06 
Weight (kg) 75.0 (16.4) 85.6 (18.9) <0.001 
Homocysteine (μmol/l) 9.1 (2.1) 10.8 (3.6) <0.001 
Duration of hypertension  16.1 (14.3)  
Education (years)2 15.3 (2.7) 14.4 (2.7) <0.001 
% Women 70.9 58.5 0.004 
% Anti-hypert Meds  85.8  
% CVD2 0.5 13.9 <0.001 
% African American 9.2 12.2 0.30 
% APOE-ε4 29.0 29.9 0.08 
Table 1.  Sample characteristics by diagnostic category.  
1brachial pressure 
2CVD: cardiovascular disease (includes myocardial infarction, coronary artery disease, and heart failure) 
Note: a t-test was used for continuous variables; a chi-square test was used for categorical variables *28+.  
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HT individuals so as to achieve maximum cell size for cross tabula-
tion of age and HT groups. Methods for adjusting for treatment are 
defined in the results section.  
Statistical Analysis Plan  
SAS version 9.2 and Stata 11 were used for all analyses. The fol-
lowing steps were employed: (1) description of, and statistical 
comparisons between, demographic and clinical parameters of the 
NT and HT groups; (2) multiple imputation of missing PWV values; 
(3) presentation of descriptive reference group data by age and BP 
classifications; and (4) multiple regression analyses with two pur-
poses, (a) determine the statistical significance of age effects, HT 
group effects, and their interactions, and (b) determination of the 
increased prediction of PWV afforded by adding other CVD risk 
factors to the PWV equation involving age and HT parameters.  
Because of the positively skewed nature of the PWV values, 
sensitivity analyses were performed including analysis of log PWV, 
robust regression and examination of residuals and influence sta-
tistics. Diagnostic results were within acceptable values and re-
vealed no issues. The pattern of results was identical for log PWV 
and raw score data and results are reported for raw scores which 
are most directly interpretable.  
Using available CVD covariables and demographics, the imputa-
tion procedure used chained equations to construct 10 imputed 
data sets designed to provide the missing PWV data.  Results from 
analyses were combined across imputations using Rubin’s rules 
*31+. Agreement obtained with imputation and listwise deletion 
was high and the similarity of the pattern of significant results for 
the observed PWV and the imputed + observed values was high as 
discussed below. This allowed us to determine the impact of miss-
ing data on our findings and increase our sample size for a second-
ary presentation of the normative and reference value data. Miss-
ing data fractions were within statistically acceptable limits.  
RESULTS  
Sample Characteristics  
Table 1 shows the demographic and cardiovascular risk factors 
for HT and NT groups for the observed data and p-values for differ-
ences among the groups.  For most of the variables presented, 
compared to the NT cohort, persons in the HT cohort exhibited a 
higher prevalence of CVD risk factors or higher clinical values 
(p<0.05), were older (p< 0.05) and somewhat less educated 
(p<0.05), although education differences were slight in absolute 
terms.  
Preliminary Adjustment  
A majority of HT participants were treated by wave 7. In order to 
compare our data with RVASC data for subcategories of HT it was 
necessary to estimate untreated BP values.  Following Tobin et al., 
we added a “reasonable constant” to systolic and diastolic BP for 
treated HT individuals *32+. With age and BMI controlled, differ-
ences between treated and untreated systolic and diastolic values 
in our study were 8 and 4 mmHg respectively. These values were 
used as constants. Results were  essentially the same with the ad-
dition of 10 and 5 mmHg constants used in other studies *33-34+. 
Consequently, we utilized the 8 and 4 mmHg adjustment for all BP 
classifications and calculation of MAP.  To check on the effective-
ness of the adjustment we compared treated and untreated HT 
individuals with respect to PWV values after our adjustments for 
treatment and found no statistically significant effects of treatment 
(p= 0.93).  
MSLS Classifications  
Figure 1 shows a systematic rise in PWV with age and consist-
ently higher PWV values for the HT group. The top and bottom 
portions of Table 2 show, respectively, reference group data sam-
ples based on the observed and imputed PWV values. Both show 
the RVASC PWV data where comparisons are possible due to re-
porting of data for the same age groups. PWV values were higher 
for the HT participants, and increased with age within the NT and 
HT categories, and at each age the HT cohort exhibited higher PWV 
values. This same pattern was seen for medians and for the 95th 
percentile of the distribution.  Regardless of whether observed or 
imputed means are employed in the analysis, agreement with the 
RVASC study is generally good. Mean values for the RVASC study 
are within one-half SD from the MSLS means.  
Figure 1. A bar plot showing trends for age within HT and NT 
groups.  
The regression equation for the categorical regression with age 
centered was as follows: PWV = 9.152 + 0.844 × age group + 1.479 
× HT + 0.453 × age group × HT; R2 = 0.36. The age group (p< 0.001), 
HT (p<0.001) and the age group x HT (p<0.01) effects were all sta-
tistically significant.  
More Refined Diagnostic Groups  
Visual inspection indicates a high agreement between imputed 
and observed values of PWV. Consequently, using the imputed 
data we were able to achieve cell sizes sufficient to reproduce ref-
erence group data for some more specific diagnostic categories 
employed in RVASC and defined in Table 3. We show difference 
scores for PWV values for RVASC and our study. While sample size 
is quite low at younger ages for our cells representing the RVASC 
hypertension grade II/III categories, the progression of increased 
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PWV across age and HT groups is consistent with expectations. 
Deviations of RVASC mean PWV values from MSLS mean PWV 
values are within 1 SD or less of the SD values reported for MSLS. 
The trend across BP groups and age is illustrated in Figure 2.  
Figure 2. A bar plot showing trends for age within BP catego-
ries.   
Norms versus Reference Values  
RVASC investigators make a distinction between normal PWV 
values and reference group values. This is possible in the present 
study if we use the optimal or normal BP groups, or both as nor-
mative (in the sense of normal) groups. There was only one NT 
individual with CVD (diagnosed coronary artery disease in the 60 
to 69 year-old normal BP diagnostic group). Removing that individ-
ual made no difference in results obtained for this group for either 
the observed or imputed data. As an option to the normal BP 
group as a basis for “normal BP” values one may use the optimal 
BP diagnostic group (Table 3).  
Using only the observed data for the expanded regression anal-
ysis (Table 3 top), the regression equation was as follows:  PWV = 
10.059 + 1.069 × age group + 0.447 × BP diagnostic category + 
0.081 × age group × BP. Significant age group (p<0.001) and BP 
diagnostic group (p< 0.001) group interactions were observed and 
the age group x BP diagnostic group interaction p value was 0.06; 
R2=  0.38.  
Next we determined how well the RVASC equations predicted 
PWV data obtained in the MSLS. Applying the RVASC equations, 
RVASC-Table 6 top *20+, to the observed data obtained in the 
MSLS, we calculated Ŷ PWV for each subject as a function of HT or 
age. These equations accounted for 36 percent variance in our 
PWV values (R2= 0.36; p <0.001).  
Men Versus Women  
Means for PWV for men and women were 10.7 and 9.8 m/s 
respectively (p< 0.001).  Preliminary analyses indicated the ab-
sence of a quadratic effect for age, and sex did not interact signifi-
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cantly with age or HT groups (all p values> 0.14).  With adjustment 
of the full model (discussed below), the least-square means for 
men and women were 10.2 and 10.0 m/s respectively (p= 0.41).  
Expanded Models with Risk Factors  
Figure 3 presents a scatter plot and regression lines (slopes) for 
the observed data with age as a continuously distributed variable. 
The final steps in our analyses were designed to identify a parsimo-
nious regression model that would increase the prediction of PWV 
beyond that possible with age and HT parameters alone. The first 
set of variables, considered essential controls *15-21+, were fixed in 
the model:  Age + HT + (HT × Age) + Height + Weight + Heart Rate + 
MAP + Lipid Lowering Drugs (1 = drug). Anti-hypertensive treat-
ment effects were not significant and not included in the model.  
Once fixed variables were entered into the equation, candidate 
variables (footnote, Table 4) were entered with a stepwise back-
ward elimination procedure. Variables that did not enter the equa-
tion significantly (p< 0.10) via the backward elimination procedure 
were not included in the final equation.  
Figure 3.  Association between age and PWV for the hyperten-
sive (dots, solid line) and normotensive (circles, dashed line) 
groups. The regression equation for age and hypertension for 
the overall sample (with age centered) was: PWV = 9.210 + 
0.089 × age + 1.437 × hypertension + 0.041 × age × hyperten-
sion; R2 = 0.36.  
As may be seen in Table 4, also for the observed data, the basic 
age + HT + (HT × Age) model accounted for 36 percent of the vari-
ance in PWV; the final model, each variable adjusted for all others, 
accounted for 47 percent. Of all the candidate variables, only cre-
atinine and glucose entered the equation significantly with alpha =  
0.10, and account for a small portion of variance, ΔR2= 0.024.  The 
same risk factors were significant and the regression model was 
similar when the larger imputed PWV data set was employed, 
when sex (p= 0.41) was included in the model, and when other non
-significant associations were excluded.  A regression table based 
on the imputed data is not shown as the same pattern of signifi-
cant associations and R2 values was obtained.  Similarity of results 
obtained for observed and imputed values was confirmed by a 
Wald test of equality of coefficients between the least squares 
deletion model (observed values) and the multiple imputation 
model: F(10,594)= 0.05, p> .999.  
Final Analyses  
African American versus other ethnic group status did not enter 
into the regression equation significantly (p= 0.19) and the pattern 
of results was not affected by excluding African Americans from 
the sample.  
The CVD variable could not be adjusted statistically because of 
its very low prevalence in the NT groups. However, when persons 
with CVD (see Table 1) were excluded from the analyses, the 
pattern of results was nearly identical to those presented above.  
DISCUSSION  
We provide PWV normative and reference group data by NT and 
HT groups for the SphygmoCor® device, a system that uses an in-
tersecting target algorithm, a function shared with numerous other 
systems *13+. The rise in PWV with age and hypertension, and the 
interaction between hypertension and age is consistent with the 
RVASC *20+ study and others.  Our data clearly indicate the limita-
tions with respect to a focus on a single clinically significant fixed 
threshold value for elevated PWV, e.g., 12 m/s as has been recom-
mended *9+.  In our community-based study only for the 70 to 79 
year old HT group do we see mean PWV values at the recommend-
ed 12 m/s threshold value. Mean and median values for younger 
subjects (60 to 69, or younger), HT or NT, fall below this threshold.  
For the classification based on more refined diagnostic groups (see 
Table 3), only the mean values for 70+ year old, Grade I and Grade 
II/III HT individuals were at or above the 12 m/s threshold.  
The validity of the RVASC regression equations using age and HT 
parameters is exemplified by the fact that they account for almost 
the same amount of variance (36 percent) in our own PWV values, 
as do our own equations when limited to those parameters.  
Moreover, the agreement between the RVASC PWV reference 
values and ours is remarkably high given the difference in sample 
size between the studies. This finding endorses the usefulness of 
their data under circumstances where norms and reference groups 
for one’s specific device and laboratory are unavailable, but does 
not obviate the need for system-specific studies such as the pre-
sent.  Limitations elucidated by the RVASC team include two points 
relevant to this issue: (1) their mathematical calculations attenuat-
ed but did not totally abolish differences in PWV on the basis of 
different algorithms and methods for determining path length; and 
(2) there was a strong data collection center effect for PWV that 
was not accounted for by their standardization procedures.  
Our third study goal was to develop a parsimonious model, us-
ing multiple risk factors that would allow a prediction of PWV be-
yond that afforded by age and hypertension. We found that a 
group of risk factor variables readily available to most practicing 
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Covariables b SE Cumulative R2 Delta R2 
Intercept -4.772* 2.061     
Age (years)3 0.105*** 0.013 0.297   
Hypertension (1= yes) 0.117 0.258     
Hypert × Age3 0.041** 0.017 0.360 0.063 
Height (cm) 0.013 0.011     
Weight (kg) 0.018** 0.007     
Heart Rate (bpm) 0.039*** 0.011     
MAP (mmHg) 0.045*** 0.009     
Lipid Meds (1=yes) -0.315 0.209 0.450 0.090 
Creatinine (μmol/l)2 1.433** 0.532     
Glucose (mmol/l)2 0.034*** 0.009 0.4744 0.024 
Table 4.  Raw multivariable regression coefficients (b), standard errors (SE) expressing the relation-
ship between risk factors and PWV (m/s) with each b adjusted for all others.1,2  
1 8 and 4 mmHg respectively are added to treated BP levels prior to analysis; the pattern of signifi-
cant results is the same without adjustment. Findings are the same with waist circumference sub-
stituted for height+weight or in absence of adjustment for lipid medications.     
2Variables up to and including lipid medications were fixed in the model (could not be eliminated). 
Once the fixed variables were entered into the equation, the following candidate variables were 
entered into a stepwise backward elimination: education (years), plasma homocysteine (μmol/l), 
cigarettes/wk (or heavy smoking, >15/day), glucose (mmol/l), creatinine (μmol/l), triglycerides 
(mmol/l) (or other lipid values in separate analyses), alcohol consumption (g/wk), APOE genotype 
(ε4/no ε4), race/ethnicity (African American versus other), and c-reactive protein. 
3Age is centered 
4model R2 (df = 10; 485) 
*p< 0.05, **p< 0.01, ***p< 0.001 
physicians (Table 4) allowed us to account for 47 percent of the 
variance in PWV as opposed to the 36 percent accounted for by 
the age and hypertension variables. These findings are consistent 
with findings that CVD risk factors other than hypertension and 
age are predictors of PWV *6-8+. 
In terms of the question of which CVD risk factors are dominant 
with respect to the prediction of PWV, our results are consistent 
with a recent comprehensive review and meta-analysis of 65 stud-
ies *35+. The conclusion reached in this study was that the contri-
bution of risk factors to the prediction of PWV other than age, hy-
pertension, or BP is either small or non-significant. Viewed from a 
general perspective, our findings are entirely consistent with this 
conclusion. The point we wish to make in our analysis is that addi-
tional variables that account for a small percentage of variance in 
PWV beyond that accounted for by age and hypertension do in-
crease the prediction of PWV. 
 After age + hypertension, age x hypertension interactions and 
essential controls were fixed in our regression model, only glucose 
and creatinine entered into the regression model significantly. It is 
of interest that glucose was positively associated with PWV despite 
the fact that persons with diabetes mellitus were excluded from 
the analyses.  In the Caerphilly Prospective Study *6+, glucose was 
positively associated with PWV, but only at baseline. In the same 
study, creatinine, an index of kidney disease, was significantly as-
sociated with PWV both at baseline and after 20 years of follow-up 
*6+.  
Study Limitations  
As was true for the RVASC investigation, our study was limited 
because PWV was not measured longitudinally. Physicians treat 
age cohorts (people born at the same time) differently and thus 
cross-sectional norms and reference groups are of value, but longi-
tudinal data are necessary to answer the need for data relevant to 
serial treatment of the same patients over time.  
It is possible discrepancies in point estimates between RVASC 
and our study related to our smaller sample, but results were the 
same when imputation of missing data allowed us to increase sam-
ple size, and dissimilarity between our study and RVASC was not 
systematically seen as a function of cell size in our study.  
Over- or under-adjustment of BP to estimate the untreated con-
dition may have resulted from the Tobin et al. *32+ adjustment 
procedure, although the same results for various regression anal-
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yses were observed with conventional covariance analyses using 
raw scores with anti-hypertensive drug treatment as a covariate.  
Moreover, our adjustments with the purpose of obtaining untreat-
ed BP value estimates in those who were treated cannot explain 
differences between point estimates in the RVASC and MSLS stud-
ies since those differences are there for untreated NT individuals.  
We had too few participants to permit construction of norma-
tive values for African American participants. Shiburi et al. *19+ 
provides reference values by age for SphygmoCor® measurements 
obtained in South Africans of African Ancestry. Normative values in 
other cultures and minority groups need to be provided within 
extensive BP classifications as well as age groups.  
CONCLUSIONS  
Reference values for clinically significant PWV values must take 
age into account. There is relatively good agreement between 
PWV norms and reference group values for a large aggregate sam-
ple (RVASC) using multiple instruments and the much smaller MSLS 
sample, but an inexact match for within-cell PWV values confirms 
the need for normative and reference group values derived in 
one’s own region with one’s own measuring device. From an actu-
arial prospective, predicting PWV from CVD risk factors, the largest 
proportion of the best predictions of PWV values may be based on 
relatively few CVD risk factors readily available to most diagnostic 
and treatment centers.  
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